MEDLINE Mobility products, which have been a staple of many medical offices since the 1990s, have filed a class action lawsuit against Medline Mobility Products, alleging the company deceived consumers and misled them into buying the products.
The suit was filed in U.S. District Court in Atlanta, Georgia.
The plaintiffs are represented by John A. Gebhart, of Georgia-based Gebhard, Gebhardt & Partners, in Atlanta.
Medline Mobility products were sold in offices from 2000 to 2012.
The products are available through the Medline Pharmacy and Healthcare Products, Inc. brand, but are sold separately through the company’s online pharmacy, G2, and its website, Medline Health.
The lawsuit states that the products are not subject to Medline’s quality assurance process and contain potentially harmful ingredients, including lead, mercury, lead paint, arsenic and other toxic metals.
The complaint says that the Medlines marketing materials, which are printed on the back of the products, mislead consumers into thinking they were purchasing safe and effective medications when they were in fact purchasing potentially harmful medications.
The lawsuit seeks an injunction barring Medline from using the Medlabs logo on Medline products and from labeling the Medlinys products as being made in the United States.
It seeks an order prohibiting Medline, its subsidiaries and employees from selling the products to anyone who does not reside in the country.
A Medline spokeswoman did not immediately respond to a request for comment.
The Medline mobility product is not the only one to come under scrutiny by the lawsuit.
On Tuesday, a New York-based health insurance company, Medica, filed a similar lawsuit against the MedLine company in federal court in New York City.
In addition to the Medlis, Medlins and Medlinks brands, Medlan has been sued by companies including Aetna, Amgen, Allstate, Aetolia, Amstar, and Anthem.
Medlans products have also come under fire for not meeting safety standards, including an annual cap of $7,500 on claims.